| Home | E-Submission | Sitemap | Contact Us |  
The Korean Journal of Medicine 2009;76(2): 137-142.
골수이형성증의 NCCN 치료지침과 최적의 보조요법
The NCCN clinical practice guidelines and best supportive care for the myelodysplastic syndromes
Chul Won Choi
The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem-cell disorders characterized by peripheral cytopenias and hypercellular, dysplastic bone marrow. Appropriate treatment of cytopenia, as well as of other related complications, affect the overall survival of patients. The best supportive care including red blood cell or platelet transfusions and antibiotics have been the most frequent treatment given for patients with MDS. Now new drugs have recently been approved for treating specific subtypes of MDS. Because the choice of therapy and the decision to begin treatment must be tailored to each patient, specific practice guidelines based on extensive evaluation of the data are warranted for both patients and treating physicians. Here, the National Comprehensive Cancer Network (NCCN) clinical practice guidelines for the MDS and currently available options for the best supportive care have been reviewed. (Korean J Med 76:137-142, 2009)
Keywords: Myelodysplastic syndromes; Practice guideline
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
Supplementary Material  Supplementary Material
Significance of cytogenetics in myelodysplastic syndromes  2009 February;76(2)
Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes  2009 February;76(2)
New agents for the treatment of myelodysplastic syndromes  2009 February;76(2)
Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6791   Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Association of Internal Medicine. All rights reserved.                powerd by m2community